Volume 90 Issue 16 | p. 8 | News of The Week
Issue Date: April 16, 2012

Amgen Will Buy Peptide Firm Kai

Biopharmaceuticals: Acquisition adds a late-stage therapeutic to the biotech’s pipeline
Department: Business
Keywords: biotechnology, biosimilars, M&A

Amgen is paying $315 million for Kai Pharmaceuticals, a privately held biotech company developing peptide therapeutics. The deal adds to a string of purchases intended to bolster the big biotech firm’s pipeline and technology portfolio.

The centerpiece of the latest acquisition is KAI-4169, a therapeutic peptide for the treatment of hyperparathyroidism in people undergoing dialysis for chronic kidney disease. An intravenous version of KAI-4169, a calcium-sensing receptor agonist, is poised to enter Phase III trials, . . .

To view the rest of this content, please log in with your ACS ID.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society